Among the PGs, PGE 2 is considered especially important for implantation and decidualization. Four major PGE 2 receptor subtypes, EP 1 , EP 2 , EP 3 , and EP 4 , mediate various PGE 2 effects via their coupling to distinct signaling pathways. Previously, we have shown that the EP 1 , EP 3 , and EP 4 genes are expressed in the periimplantation mouse uterus in a spatio-temporal manner, suggesting compartmentalized actions of PGE 2 during this period. In this study, we examined the expression of the EP 2 gene in the mouse uterus during the periimplantation period (days 1-8) and during experimentally induced progesterone (P 4 )-maintained delayed implantation and its resumption by 17␤-estradiol (E 2 ). We also examined its regulation in the uterus by ovarian steroid hormones. Our results establish that EP 2 messenger RNA (mRNA) is expressed exclusively in the luminal epithelium primarily on day 4 (the day of implantation) and day 5 (early implantation) of pregnancy. In (P 4 )-maintained delayed implanting mice, EP 2 mRNA was present in the luminal epithelium, and the expression was further enhanced regardless of the location of the blastocysts after reinitiation of implantation. This observation suggests little or no embryonic influence in regulating EP 2 expression and, instead, shows its regulation by P 4 and E 2 . Indeed, treatment with E 2 and/or P 4 exhibited unique regulation of this gene. The treatment of adult ovariectomized mice with E 2 down-regulated the basal levels of EP 2 mRNA, whereas that with P 4 up-regulated its levels in the luminal epithelium. The up-regulation of EP 2 mRNA levels by P 4 was further augmented by superimposition of the E 2 treatment, suggesting a synergistic interaction between E 2 and P 4 in regulating this gene in the uterus. Collectively, the results suggest that EP 2 could be a potential mediator of PGE 2 actions in regulating luminal epithelial differentiation and serve as a marker for uterine receptivity for implantation. (Endocrinology 138: 4599 -4606, 1997) S YNCHRONIZED development of the embryo to the blastocyst stage and preparation of the uterus for the receptive state are key to the process of successful implantation (1, 2). Coordinated effects of ovarian estrogen and progesterone (P 4 ) in a temporal and cell type-specific manner make the uterus receptive to blastocyst implantation. In the mouse, uterine receptivity for implantation occurs on day 4 (day 1 ϭ vaginal plug) of pregnancy when the luminal epithelial cells cease to proliferate and become differentiated, as opposed to entrance of stromal cells into mitosis (3). In this species, the first conspicuous sign for the initiation of implantation (attachment reaction) is increased endometrial vascular permeability at the site of blastocyst apposition that occurs in the evening (2300 -2400 h) of day 4 (1). This is followed by extensive proliferation and differentiation of uterine stromal cells into decidual cells.
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The vasoactive, mitogenic, and/or differentiating properties of PGs (4) place these lipid molecules as potential mediators of increased endometrial capillary permeability, epithelial cell differentiation, and stromal cell proliferation/ differentiation to decidualization during early events of implantation (5, 6) . PGs are derived from arachidonic acid by the cyclooxygenases (COX) pathway. COX, which exists in two isoforms, COX-1 and COX-2, is the rate-limiting enzyme in the biosynthetic pathway that converts arachidonic acid into PGH 2 . PGH 2 is then converted by specific PG synthases into diverse PG isoforms, including PGE 2 , PGF 2␣ , PGD 2 , and PGI 2 (4) . These PGs exert diverse effects through their G protein-coupled cell surface receptors (7) . Among the PGs, PGE 2 mediates many biological functions in cardiovascular, pulmonary, renal, endocrine, gastrointestinal, neural, reproductive, and immune systems (8) . PGE 2 can bind to and activate a set of functionally distinct cell surface receptors, EP 1 , EP 2 , EP 3 , and EP 4 , which are classified on the basis of their responses to various agonists and antagonists to PGE 2 . They also exhibit different characteristics with respect to their structures, tissue distribution, and signal transduction mechanisms (7) . Thus, EP 1 is coupled to Ca 2ϩ mobilization, whereas both EP 2 and EP 4 subtypes are coupled to the stimulation of adenylyl cyclase via G s . In contrast, EP 3 is coupled to G i , which inhibits adenylyl cyclase activity. Cell surface receptors for PGF 2␣ , PGD 2 , PGI 2 , or thromboxane have also been identified as FP, DP, IP, and TP, respectively (9 -12) .
Previously, we demonstrated that EP 1 , EP 3 , EP 4 , and FP genes are expressed in the mouse uterus during the periimplantation period in a spatio-temporal manner (13) . The expression of EP 3 and FP in the circular muscle of the myo-metrium on days 3-5 suggested that this muscle layer is the target for PG-mediated uterine contractions required for embryo transport and spacing. In contrast, the expression of EP 3 in a subpopulation of stromal cells at the mesometrial pole and of EP 4 in the epithelium and stroma on these days suggested that the activation of these receptor subtypes by PGE 2 could be important for preparation of the uterus for implantation. Further, expression of EP 1 , EP 3 , and EP 4 in site-specific decidual cells during the postimplantation period suggested PGE 2 's role in various aspects of decidualization process. However, information regarding the expression of EP 2 , an important member of the PGE 2 receptor subtypes, in the uterus is very limited, except for a report describing the expression of this messenger RNA (mRNA) in the mouse uterus during pseudopregnancy (14) . However, data concerning whether the expression of this gene in the uterus is influenced by developing embryos, ovarian steroids, and/or decidualization are totally lacking. In the present investigation, we examined the temporal and cell-specific expression of the EP 2 gene in the mouse uterus during the periimplantation period (days 1-8 of pregnancy) as well as its regulation during experimentally induced delayed implantation and after termination of the delayed implantation. We also examined the regulation of this gene in the ovariectomized adult uterus by estrogen and P 4 . The results establish that EP 2 is associated with the luminal epithelial cell differentiation that is necessary for blastocyst implantation and that this gene is regulated synergistically by estrogen and P 4 , but not by developing and/or implanting embryo.
Materials and Methods

Animals and tissue preparation
CD-1 mice (Charles River Laboratories, Raleigh, NC) were housed in the animal care facility at the University of Kansas Medical Center in accordance with NIH standards for the care and use of experimental animals. Adult females were mated with fertile males of the same strain to induce pregnancy (day 1 ϭ vaginal plug). Mice on days 1-8 were killed at 0900 h, and their uteri were collected for RNA preparation and in situ hybridization. Pregnancy on days 1-4 was confirmed by recovering embryos from the reproductive tracts. On days 5 and 6, implantation sites were identified by monitoring the localized uterine vascular permeability at the sites of blastocysts after iv injection of Chicago blue B solution in saline. Implantation sites were demarcated by discrete blue bands along the uterus (2). On days 7 and 8, implantation sites were distinct, and their identification did not require any special manipulation. To examine the effects of neutralization of P 4 or estrogen effects on EP 2 expression during the preimplantation period, pregnant mice received sc either an injection of RU-486 (400 g/mouse; Roussel-UCLAF, Romaineville, France), a P 4 receptor (PR) antagonist, on days 3 and 4 at 0900 h or an injection of ICI 182780 (50 g/mouse; ICI Pharmaceuticals, Macclesfield, UK), a specific estrogen receptor (ER) antagonist, on day 4 at 0900 h. The control mice received the vehicle (0.1 ml oil/mouse) on days 3 and 4. They were killed on day 5 at 0900 h after injections of a blue dye solution to examine implantation sites, and uteri were collected for in situ hybridization.
To induce and maintain delayed implantation, mice were ovariectomized at 0800 -0900 h on day 4 of pregnancy and received daily injections of P 4 from days 5-7 (2 mg/mouse; Sigma Chemical Co., St. Louis, MO) (2, 15) . To terminate delayed implantation and to induce blastocyst activation, the P 4 -primed delayed implanting mice were given an injection of 17␤-estradiol (E 2 ; 25 ng/mice; Sigma) on the third day of the delay (day 7). Mice were killed 24 h after treatment with the respective steroid hormones, and their uteri were collected for in situ hybridization. The first visually detectable implantation sites after blue dye injection become evident 18 -24 h after an E 2 injection.
To determine the effects of estrogen and P 4 , mice were ovariectomized regardless of the stage of estrous cycle and rested for 2 weeks. They were treated with P 4 (2 mg/mouse) for 2 days with or without an injection of E 2 (100 ng/mouse) on the second day of P 4 treatment. To neutralize the effects of P 4 or E 2 , mice were injected with RU-486 (400 g/mouse) or ICI-182780 (50 g/mouse), respectively. Control animals received vehicle (0.1 ml oil/mouse) only. Mice were killed 24 h after the last injection, and their uteri were collected for in situ hybridization. All steroids and antagonists were dissolved in sesame oil and injected sc (0.1 ml/mouse).
Hybridization probes
A mouse-specific complementary DNA to EP 2 was generously provided by Dr. Ichikawa (Kyoto University, Kyoto, Japan) (16) . For Northern hybridization, antisense 32 P-labeled complementary RNA (cRNA) probe was generated, whereas for in situ hybridization, sense or antisense 35 S-labeled cRNA probe was generated using appropriate polymerases. A part of the ribosomal protein L7 (rpL7) complementary DNA was subcloned into pCR-Script vector containing promoter for T7 polymerase and used as a template for synthesis of 32 P-labeled antisense rpL7 RNA probe (17) . The probes had specific activities of about 2 ϫ 10 9 dpm/g.
Northern blot hybridization
Total RNA was extracted from uteri by a modified guanidine thiocyanate procedure (18, 19) . Polyadenylated [poly (A) ϩ ] RNA samples were isolated by oligo(deoxythymidine)-cellulose column chromatography (20) . Poly(A) ϩ RNA samples (2.0 g) were denatured, separated by formaldehyde-agarose gel electrophoresis, transferred, and crosslinked to nylon membranes by UV irradiation. Northern blots were prehybridized and hybridized as described previously (21) . Briefly, hybridization was carried out for 20 h at 68 C in 3 ϫ SET (1 ϫ SET ϭ 150 mm NaCl, 5 mm EDTA, and 10 mm Tris-HCl, pH 8.0), 20 mm phosphate buffer (pH 7.2), 250 g/ml transfer RNA, 10% dextran sulfate, and approximately 2 ϫ 10 6 counts/min of 32 P-labeled antisense RNA probe/ml hybridization buffer. After hybridization, the blots were washed once in 1 ϫ SSC (standard saline citrate)-0.1% SDS for 1 h at 68 C, followed by a second washing in 0.3 ϫ SSC-0.1% SDS for 1 h under the same conditions, and the hybrids were detected by autoradiography. Stripping of the hybridized probe before subsequent rehybridization was achieved as described previously (21) . Each blot was first hybridized to the EP 2 probe and then to the rpL7 probe (a housekeeping gene) to confirm integrity, equal loading, and blotting of RNA samples. Northern blot hybridization experiments were repeated three times using independent RNA samples.
In situ hybridization
In situ hybridization was performed as described previously (17, 18) . Frozen uterine sections (10 m) were mounted onto poly-l-lysinecoated slides and stored at Ϫ70 C until used. When required, frozen sections were cut serially to detect the sites of blastocysts. After removal from Ϫ70 C, the slides with the uterine sections were placed on a slide warmer (37 C) for 1 min and then fixed in 4% paraformaldehyde in PBS for 15 min at 4 C. After prehybridization, uterine sections were hybridized to 35 S-labeled antisense EP 2 cRNA probe for 4 h at 45 C. As negative controls, uterine sections were hybridized with the 35 S-labeled sense probe. After hybridization and washing, the slides were incubated with ribonuclease A (RNase A; 20 g/ml) at 37 C for 20 min. RNase A-resistant hybrids were detected within 3-5 days of autoradiography using Kodak NTB-2 liquid emulsion. The slides were poststained with hematoxylin and eosin. In situ hybridization experiments were repeated at least twice, using independent samples.
Results
Northern blot analysis of the EP 2 mRNA in the periimplantation uterus
Steady state levels of the EP 2 mRNA in the periimplantation uterus (days 1-8) were analyzed by Northern blot hybridization using 32 P-labeled mouse EP 2 antisense cRNA probe (Fig. 1) . As reported previously (16), two transcripts (2.2 and 2.8 kilobases) were detected in poly(A) ϩ -enriched whole uterine RNA samples. EP 2 mRNAs were primarily detected on days 4 and 5 of pregnancy, preceded or followed by very low levels of expression on other days of pregnancy.
In situ hybridization analysis of the EP 2 mRNA in the periimplantation uterus
In situ hybridization study revealed distinct temporal and cell-specific localization of the EP 2 mRNA during the periimplantation period. On days 1 (Fig. 2, A and B ) and 2 (data not shown), no specific signals for EP 2 mRNA were detected in any uterine cell type. In contrast, weak signals were first detected exclusively in the luminal epithelium on day 3 (data not shown) followed by augmentation of these signals on days 4 and 5 of pregnancy (Fig. 2, C-F) . Furthermore, the signals were present throughout the luminal epithelium regardless of the location of blastocysts. No accumulation, however, was noted in the glandular epithelium. Autoradiographic signals were also not observed in decidualizing stroma during the postimplantation period (days 6 -8); only the remaining luminal epithelium exhibited signals for this mRNA during this period. The photomicrographs for day 6 are shown (Fig. 2, G and H) . The heightened signals in the luminal epithelium on days 4 and 5 are consistent with the results of Northern blot hybridization (Fig. 1) . No positive autoradiographic signals were detected in sections hybridized with the sense probe (data not shown).
These results provided evidence that the increased luminal epithelial EP 2 mRNA levels on days 4 and 5 are correlated with rising P 4 levels and preimplantation estrogen secretion on the morning of day 4. This is further supported by our observation of inhibition of implantation and drastic downregulation of luminal epithelial accumulation of EP 2 mRNA on day 5 after treatment with RU-486, a PR antagonist, on days 3 and 4 of pregnancy (Fig. 3 , compare A and B vs. C and D). An interference with estrogen functions by ICI 182780, an ER antagonist, on day 4 also inhibited implantation on day 5 and down-regulated the luminal epithelial accumulation of this mRNA (Fig. 3, E and F) . However, this down-regulation was modest than when P 4 effects were neutralized.
In situ hybridization of EP 2 mRNA in the delayed implanting uterus before and after the initiation of implantation
To determine whether the short window of unique cell type-specific localization of EP 2 mRNA is under embryonic regulation, in situ hybridization was performed on uterine sections obtained from P 4 -treated delayed implanting mice or after the initiation of blastocyst activation and implantation by an E 2 injection (Fig. 4) . Autoradiographic signals were detected along the entire uterine luminal epithelium of P 4 -treated delayed implanting mice (Fig. 4, A and B ). Signals were greatly augmented when the implantation process was resumed by an injection of E 2 (Fig. 4, C and D) . However, this up-regulation was again noted regardless of the location of the activated blastocysts. This suggested that luminal epithelial expression of EP 2 mRNA is regulated primarily by steroid hormones, but not by resident blastocysts.
Regulation of the EP 2 mRNA by ovarian steroid hormones
To further confirm that the EP 2 gene in the uterus is primarily regulated by ovarian steroid hormones, adult ovariectomized mice treated with E 2 alone, or P 4 for 2 days with or without E 2 (Fig. 5, A-D) were used. Mice were killed 24 h after the last injection, and in situ hybridization was performed on uterine sections. Basal levels of EP 2 mRNA accumulation were observed in the luminal epithelium of ovariectomized mice treated with oil (vehicle) only (Fig. 5A) . Although a single injection of E 2 down-regulated this basal level of expression, treating the mice with P 4 for 2 days up-regulated the level of this mRNA in the luminal epithelium (Fig. 5, B and C) . Furthermore, this P 4 -up-regulated EP 2 mRNA expression was remarkably enhanced when E 2 treatment was superimposed on P 4 priming (Fig. 5D ). P 4 induction of EP 2 mRNA was attenuated by prior treatment of mice with a PR antagonist, RU-486 (Fig. 5E ). In contrast, although treatment with this P 4 antagonist greatly reduced the levels of EP 2 mRNA in P 4 -plus E 2 -treated uterus (Fig. 5F ), treatment with a specific estrogen antagonist, ICI-182780, maintained levels comparable to those observed in P 4 -onlytreated uterus (Fig. 5G) . These results suggest that P 4 is the prime regulator of the EP 2 gene in the luminal epithelium, although a cooperative effect of E 2 is operative only when it is superimposed upon P 4 priming. The results obtained from normal pregnancy and delayed implantation models support this unique pattern of steroidal regulation of EP 2 in the uterus.
Discussion
The highlights of the present investigation are that the PGE 2 receptor subtype EP 2 is expressed exclusively in the mouse uterine epithelium in a temporal manner during the periimplantation period and that this unique expression pattern is obtained by a well orchestrated effect of P 4 and E 2 . The establishment of the receptive uterus is achieved by the coordinated actions of P 4 and E 2 in a temporal and cell-specific manner. In the mouse, the uterus on days 1 and 2 of pregnancy is under the influence of the preovulatory estrogen surge that directs proliferation of the epithelium. In contrast, S-labeled antisense cRNA probe. RNase A-resistant hybrids were detected by autoradiography after 3 days of exposure. Uterine EP 2 mRNA distribution on days 1 (A and B), 4 (C and D), 5 (E and F), and 6 (G and H) of pregnancy is shown in brightfield (left column) and darkfield (right column) photomicrographs at ϫ100. le, Luminal epithelium; ge, glandular epithelium; s, stroma; myo, myometrium; pdz, primary decidual zone; bl, blastocyst; em, embryo; M, mesometrial side; AM, antimesometrial side. rising levels of P 4 from newly formed corpora lutea result in switching of the proliferation from the epithelium to the stroma on day 3 of pregnancy, which is further stimulated by preimplantation estrogen secretion on day 4 (3). This superimposition of estrogen on P 4 priming appears to direct epithelial cell differentiation, which is essential for blastocystuterine interactions during the initial events of implantation. The beginning of EP 2 mRNA expression exquisitely in the luminal epithelium on day 3 and its remarkable increase on day 4 (the day of the attachment reaction) suggest that PGE 2 action via activation of this receptor subtype is involved in the differentiation of the luminal epithelium required for implantation. This assumption is consistent with the fact that PGE 2 acts as a differentiating factor for different cell types of epithelial origin (22, 23) . Furthermore, persistent expression of this gene on day 5 could be implicated in the maintenance of luminal epithelial differentiation during the early events of the implantation process. In this regard, the disruption of implantation by RU-486 or ICI 182780 was associated with down-regulation of luminal epithelial accumulation of EP 2 , reinforcing the idea that EP 2 could be associated with the luminal epithelial cell differentiation that is required for implantation. The elevated uterine levels of COX-1 expression on day 4 and of COX-2 at the implantation sites on day 5 (24) suggests that PGE 2 should be available to exert its action via EP 2 .
Both PGE 2 and cAMP are known to be involved in stromal cell proliferation and decidualization (5, 6, 25) . As the deepitheliated uterus fails to undergo decidualization in response to experimental stimuli, a signal(s) emanating from the luminal epithelium has been considered important for the initiation of stromal cell decidualization (26) . Thus, it is possible that elevated levels of cAMP resulting from the activation of epithelial EP 2 by PGE 2 may participate in transmission of the luminal epithelial cell signals to the stroma for decidualization. On the other hand, there is evidence that information emanating from the stroma also influences epithelial cell functions (27) . Thus, a cross-talk between the luminal epithelium and stroma by the coordinated actions of epithelial EP 2 and stromal EP 4 (13) , both of which are coupled to stimulation of adenylyl cyclase, could be important for the initiation of implantation and decidualization. The induction of implantation by intraluminal injection of (Bu) 2 cAMP in the P 4 -maintained delayed implanting mice in the absence of estrogen (28) or rapid increases in intracellular cAMP after induction of decidual cell reaction in the hormonally primed uterus (25) is supportive of this possibility.
Our study using the experimentally induced delayed implantation model demonstrates that uterine expression of EP 2 is not influenced by either dormant or activated blastocysts; rather, this expression is regulated by ovarian steroids P 4 and/or E 2 . The similar expression pattern of EP 2 in the pseudopregnant mouse uterus (15) as that in the pregnant uterus on days 4 and 5 reinforces the fact that this gene in the mouse uterus is primarily regulated by steroid hormones. Our present investigation further demonstrates that the EP 2 gene is regulated uniquely in the uterus by P 4 and E 2 , in that
In situ hybridization of the EP 2 mRNA in steroid-treated adult ovariectomized uterus in the absence or presence of specific antagonists. Ovariectomized mice were given a single injection of sesame oil (0.1 ml/mouse), E 2 (100 ng/mouse), or P 4 (2 mg/mouse) for 2 days with or without an E 2 injection on the last day of treatment, and mice were killed 24 h after the last injection. An injection of PR antagonist (RU-486) or ER antagonist (ICI-182780) was given 30 min before each steroid injection. Darkfield photomicrographs of representative longitudinal uterine sections are shown at ϫ100. A, Oil (control); B, E 2 ; C, P 4 ; D, P 4 plus E 2 ; E, RU-486 plus P 4 ; F, RU-486, P 4 , and E 2 ; G, ICI-182780, P 4 , and E 2 . le, luminal epithelium; s, stroma; myo, myometrium. P 4 up-regulates its expression, and E 2 further potentiates this P 4 effects, although E 2 alone down-regulates the expression. The effects of P 4 and E 2 could be either synergistic or antagonistic with respect to various uterine functions and gene expression in a temporal and cell-specific manner. For example, synergistic and antagonistic effects of P 4 and E 2 on epithelial and stromal cell proliferation and/or differentiation, and their antagonistic effects on epithelial Muc-1, lactoferrin, amphiregulin, and erbB2 genes are well documented (3, 17, 21, 29, 30) . As both P 4 and estrogen are essential for implantation in the mouse, synergistic as well as antagonistic effects of these steroids at the molecular and cellular levels appear to be essential for successful implantation. The upregulation of EP 2 in the luminal epithelium by P 4 and E 2 is the first example of true synergism between these two steroids at the molecular level in preparing the uterus for implantation. Synergistic modulation of the EP 2 gene by P 4 and E 2 is consistent with its expression pattern in normal pregnant uterus on days 4 and 5 when the uterus has been exposed to rising P 4 levels and preimplantation estrogen secretion. The effects of P 4 and/or E 2 on uterine EP 2 expression is mediated by classical nuclear PR and ER, as PR and ER antagonists abrogated the effects of P 4 and/or E 2 . Although synergistic and antagonistic cross-talk between ER and PR in gene expression has been studied (31, 32) , better understanding of this cross-talk requires further investigation. In this respect, the EP 2 should serve as a candidate gene to study synergism between steroid hormone receptors.
Our previous and present investigations point toward the importance of ligand receptor signaling with PGs in the process of implantation and decidualization, and these events are attributes of the compartmentalized generation of PGs and/or expression of their receptors in the uterus during the periimplantation period. Application of PGE 2 receptor subtype-specific antagonists or targeting of these genes by homologous recombination will address their definitive roles in implantation and uterine biology.
